Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF NOVEMBER 28, 2002 FBO #0361
SOLICITATION NOTICE

A -- Re-Issue, Early Clinical Trails of Imaging Agents

Notice Date
11/26/2002
 
Notice Type
Solicitation Notice
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 
ZIP Code
20852
 
Solicitation Number
N01-CM-37008
 
Archive Date
9/30/2003
 
Point of Contact
Kathy Giuliano, Contract Specialist, Phone (301) 435-3821, Fax (301) 402-6699, - MaryAnne Golling, Contracting Officer, Phone (301) 435-3819, Fax (301) 402-6699,
 
E-Mail Address
kg109o@nih.gov, mg345x@nih.gov
 
Description
The Biomedical Imaging Program (BIP), Division of Cancer Diagnosis and Treatment (DCTD), National Cancer Institute (NCI) is reissuing this RFP to develop contracts to support Phase 1(Safety) and Phase 2(Preliminary Clinical Efficacy) clinical trials of promising imaging agents. These clinical trials will be used to rapidly evaluate the safety and diagnostic imaging capabilities of promising imaging probes, ligands, radiopharmaceuticals, and contrast agents that are of interest to NCI. The Safety and Preliminary Clinical Efficacy Imaging Clinical Trials contracts will create an infrastructure poised to rapidly evaluate molecularly-targeted imaging agents used to assess therapeutic anticancer agents on their molecular targets and determine clinically relevant correlates. The objectives of this program are: to rapidly conduct clinical trials necessary to assess the safety of promising imaging agents; to rapidly conduct clinical trials necessary to assess the diagnostic imaging capabilities and preliminary efficacy of promising imaging agent to characterize the molecular interactions of new molecular imaging agents with their targets through biopsies, assays, and other appropriate technologies and correlate those effects with clinically-relevant endpoints; to develop new scientific insights into molecular pathways and determinants of the relationship of the targeted imaging agents to therapeutic drug response. Major emphasis shall be on imaging agents which are found to be safe and provide important structural, metabolic, or molecular imaging data which will be important and useful in the management of patients with cancer. These Phase 1 and Phase 2 clinical trials will obtain the necessary data to fulfill the Food and Drug Administration (FDA) criteria to eventually become an approved and potentially marketable imaging agent for specific imaging indications. The studies will explore promising imaging agents, and require rapid initiation, completion, and data reporting. These contracts will also require the ability to implement correlative studies validating the localization of the investigational imaging agents on their molecular target in tumors. Imaging agents may originate from investigators not affiliated with clinical sites. The Government anticipates that three (3) contracts will be awarded on an incrementally funded basis for four years. The size of each trial might vary depending on consultation with the FDA for each specific agent. The typical size for each Safety trail will be approximately 10 patients. The typical size for each Preliminary Clinical Efficacy trail is estimated to be 25 patients. NAICS Code No. 621512 with a size standard of $11.5.Million. The solicitation is scheduled for electronic release approximately December 18, 2002. The RFP may be accessed through internet address http://rcb.nci.nih.gov/. It is the offeror?s responsibility to monitor the above internet site for the release of this solicitation and amendments, if any. POTENTIAL OFFEROR?S WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. CONTRACTORS THAT SUBMITTED PROPOSALS FOR ORIGINAL RFP N01-CM-27018, NEED NOT APPLY Point of contact: Kathleen Giuliano, Contract Specialist at e-mail: giuliank@mail.nih.gov/ Fax: 301-402-6699; Telephone: 301-435-3821. No collect calls will be accepted.
 
Place of Performance
Address: Contractor Facility
 
Record
SN00211398-W 20021128/021126213203 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.